Abbott Q2 Profit More Than Doubles As Medical Device Sales Rebound

  • Abbott Laboratories ABT Q2 profit more than doubled to $2.1 billion due to strength in its diagnostics business and a rebound in medical device sales.
  • As curbs lift and vaccinations gather, demand for medical devices is returning as more people opt for non-urgent procedures.
  • Adjusted EPS of $1.17 beat the consensus estimate of $1.02 and $0.57 reported a year ago.
  • Sales $10.2 billion beat the estimate of $9.7 billion and increased 39.5% on a reported basis and 35% on an organic basis.
  •  The company recorded sales growth of more than 11%, excluding COVID testing, on an organic basis in the quarter compared to pre-pandemic levels.
  • Diagnostics business grew nearly 63% to $3.3 billion, with COVID-19 testing-related sales at $1.3 billion, down from the previous quarter.
  • Medical Devices sales increased 51.3% to $3.7 billion on a reported basis and 45.1% organically, led by double-digit growth in Electrophysiology, Heart Failure, Structural Heart, and Diabetes Care.
  • Outlook: It maintained its 2021 adjusted earnings forecast of $4.30 to $4.50 per share from continuing operations, versus analyst consensus of $4.36.
  • Price Action: ABT shares are up 0.44% at $119.30 during the premarket session on the last check Thursday.
  • Photo by Darko Stojanovic from Pixabay
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsNewsGuidanceHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!